As at all times with these press releases be sure to learn every part and particularly the bit that defines Forward Looking Statements
November 10, 2020 10:45 AM Eastern Standard Time
TORONTO–(BUSINESS WIRE)–NEO is worked up to announce that Cybin Inc. (“Cybin” or the “Company”), a number one Toronto-based biotech and life sciences firm targeted on psychedelic pharmaceutical therapies, has made its debut on the worldwide public markets at present. Cybin is now buying and selling on the NEO Exchange below the image NEO:CYBN.
“The potential of psychedelic therapies has never been more significant, and we continue to advance these promising potential treatments through clinical development”
The Company just lately closed a CDN$45 million subscription receipt financing in relation to its reverse takeover transaction, which marked the biggest subscription receipt financing within the Canadian psychedelic sector. The Company focuses on psychedelic drug improvement, distinctive supply mechanisms, improved novel compounds, and protocols that focus on psychiatric and neurological situations.
Supported by a administration and advisory group with experience within the psychedelic, pharmaceutical and nutraceutical sectors, Cybin is working alongside the Canadian Centre For Psychedelic Science to check the security and efficacy of psilocybin-based microdosing. The Canadian Centre For Psychedelic Science is chargeable for a number of the first printed analysis on microdosing in Canada.
“Today marks a meaningful milestone for our company, as our shares begin trading on the NEO Exchange under the ticker symbol CYBN,” acknowledged Doug Drysdale, Chief Executive Officer of Cybin. “The NEO Exchange shares our passion for innovation and provides a broad platform for our next stage of growth. Cybin is heading into a very active period with the pending start of a Phase 2 clinical study of sublingual psilocybin for the potential treatment of Major Depressive Disorder. This work will take place in Jamaica with the University of West Indies. Our listing on NEO gives us increased access to capital, enhanced visibility with the investment community and, most importantly, a greater opportunity to bring innovative new treatment options to market.”
“The potential of psychedelic therapies has never been more significant, and we continue to advance these promising potential treatments through clinical development,” continued Drysdale.
Investors can commerce shares of NEO:CYBN via their traditional funding channels, together with low cost brokerage platforms and full-service sellers.
“As a leader in a ground-breaking industry, Cybin is a true innovator that brings great hope to our world,” mentioned Jos Schmitt, President and CEO of NEO. “Their values and approach align well with the NEO Exchange as we, too, continue to challenge the status quo and push boundaries to make, in our case, Canadian capital markets better for everyone. We look forward to providing Cybin with greater access to capital to sponsor clinical trials and work towards potential new therapies. The NEO Exchange is honoured to be selected by Cybin as their main board exchange of choice and will continue to deliver tangible and innovative solutions to help them and our other listing partners thrive.”
The NEO Exchange is dwelling to over 100 company and ETF listings, and constantly facilitates greater than 12 per cent of all Canadian buying and selling quantity. Click here for a whole view of all NEO-listed securities.
About Cybin Inc.
Cybin is a life sciences firm advancing psychedelic pharmaceutical therapies for varied psychiatric and neurological situations. Cybin is creating applied sciences and supply techniques aiming to enhance bioavailability to realize the specified results of psychedelics at low dosage ranges. The new supply techniques are anticipated to be studied via scientific trials to verify security and efficacy.
About NEO Exchange
The NEO Exchange is a progressive inventory alternate that brings collectively traders and capital raisers inside a good, environment friendly, and service-oriented atmosphere. Fully operational since June 2015, the NEO Exchange places traders first and offers entry to buying and selling all Canadian-listed securities on a degree enjoying subject. The NEO Exchange lists senior corporations and funding merchandise in search of a inventory alternate that permits investor belief, high quality liquidity, and broad consciousness together with unfettered entry to market information.
Forward Looking Statements
Certain statements on this press launch represent forward-looking data. All statements apart from statements of historic truth contained on this press launch, together with, with out limitation, these concerning the power to obtain all mandatory approvals, the bioavailability and potential use of the oral movie supply system, the potential security and efficacy of psilocybin administered in an orally-dissolving movie, analysis and scientific trial packages, statements concerning Cybin’s future, technique, plans, goals, objectives and targets, and any statements preceded by, adopted by or that embody the phrases “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or related expressions or the detrimental thereof, are forward-looking statements. These statements aren’t historic details however as an alternative symbolize solely Cybin’s expectations, estimates and projections concerning future occasions. These statements aren’t guaranteeing future efficiency and contain assumptions, dangers and uncertainties which are tough to foretell. Therefore, precise outcomes could differ materially from what’s expressed, implied or forecasted in such forward-looking statements. The forward-looking data and forward-looking statements included on this press launch are made as of the date of this press launch. The Company doesn’t undertake an obligation to replace such forward-looking data or forward-looking data to mirror new data, subsequent occasions or in any other case until required by relevant securities regulation.
Cybin makes no medical, therapy or well being profit claims about Cybin’s proposed merchandise. The U.S. Food and Drug Administration, Health Canada or different related regulatory authorities haven’t evaluated claims concerning psilocybin or nutraceutical merchandise. The efficacy of such merchandise haven’t been confirmed by FDA, Health Canada, or different related regulatory authority authorised analysis. There is not any assurance that using psilocybin or nutraceuticals can diagnose, deal with, remedy or stop any illness or situation. Vigorous scientific analysis and scientific trials are wanted. Cybin has not performed scientific trials for using its proposed merchandise. Any references to high quality, consistency, efficacy and security of potential merchandise don’t indicate that Cybin verified such in scientific trials or that Cybin will full such trials. If Cybin can’t receive the approvals or analysis essential to commercialize its enterprise, it could have a cloth adversarial impact on Cybin’s efficiency and operations.